ELF Test as a universally available prognostic tool for enhanding NASH patient care

The ELF Test as a Universally Available Prognostic Tool for Enhancing NASH Patient Care

Perspectives from hepatology and endocrinology

The Enhanced Liver Fibrosis (ELF™) Test​ is the first blood test granted De Novo marketing authorization by FDA for prognosis in advanced fibrosis due to NASH​. Watch this program to hear the clinical perspectives from two clinical thought leaders on how they see the ELF Test positively impacting care for NASH patients with advanced liver fibrosis.


Roma Levy

H. Roma Levy, MS

Clinical Expert, Liver Disease
Siemens Healthineers


Scott Isaacs

Dr. Scott D. Isaacs

Endocrinologist and Obesity Medicine Specialist
Atlanta Endocrine Associates, Atlanta, GA

Mazen Noureddin

Dr. Mazen Noureddin

Director of Fatty Liver Program
Cedars Sinai, Los Angeles, CA